Stimulation of the endocannabinoid receptors 1 and 2 and the TRPV1 capsaicin receptor downstream modulates bone formation and bone resorption. Bone tissue is maintained homeostatically between osteoclast and osteoblast activity. Studies have shown that CB1 and TRPV1 stimulation elicits osteoclastogenic effects, whereas CB2 stimulation is anti-osteoclastogenic. This would seem to mean that the endocannabinoid system has a role to play in the pathogenesis and potential therapy of osteoporosis. The very same system appears likely as well to have a role to play in bone cancer. Endocannabinoid modulation reduces cell growth and enhances apoptosis, and it also reduces cell invasion and bone pain, at least in mouse models of the disease. The mechanisms underlying these apparent effects need illuminating, but hybrid molecules that target these receptors are a reasonable concept to entertain in research toward future management of bone disease. 

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome.